sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stakes in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed a Form 8.3 in compliance with the Irish Takeover Panel Act, 1997. The form reveals Vanguard's interests in Avadel Pharmaceuticals plc's securities. As of December 4, 2025, Vanguard holds 5,581,297 US$0.01 ordinary shares, representing a 5.73% stake in the company. This disclosure is mandatory as Vanguard's stake surpasses the 1% threshold required for reporting.
Recent dealings include the purchase of 3,695 shares and sale of 192 shares, each priced at 21.36 USD. The filing indicates no involvement in cash-settled or stock-settled derivative transactions at this time. Additionally, there are no indemnity or option agreements, nor attachments included with this disclosure.
This release is fundamental for stakeholders monitoring changes in ownership stakes in the context of potential future offers or strategic movements concerning Avadel Pharmaceuticals.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.